2nd Next-Generation Conjugates Summit

Temas de la conferencia
With numerous novel conjugate companies recently receiving their INDs to enter the clinic including Avidity Biosciences and Dyne Therapeutics and many more following closely in their footsteps, conjugate drugs comprising of novel payloads and targeting formats are being thrust centre stage within the bioconjugate world.

Organizador profesional (PCO)
Hanson Wade

Observaciones
Brochure: https://go.evvnt.com/1400588-3?pid=4832

Speakers: Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies Inc., Fu-An Kang, Vice President, Research, MiRecule Inc., and more

https://go.evvnt.com/1400588-2?pid=4832

Ms. Jessica Durston